文献速递消化道肿瘤与早癌肝病

术前化疗后肝脏萎缩可预测结直肠癌肝转移切除术后肝功能不全

Hepatic atrophy following preoperative chemotherapy predicts hepatic insufficiency after resection of colorectal liver metastases.
PubMed 文献 · J Hepatol · 2017-02-10

研究回顾2008—2015年459例接受术前化疗并根治性切除的结直肠癌肝转移患者,154例(34%)接受广泛术前化疗(≥7周期)。ROC分析确定萎缩程度≥10%为预测术后肝功能不全的准确界值,该界值与≥7周期术前化疗显著相关;萎缩程度≥10%与肝衰竭死亡增加相关(0%[0/374] vs 15%[13/85],p<0.001)。结论认为广泛术前化疗诱导总肝体积显著萎缩,萎缩程度≥10%是术后肝功能不全和死亡的独立预测因素。

要点

  • 广泛术前化疗(≥7周期)与总肝体积显著萎缩相关。
  • 萎缩程度≥10%是预测术后肝功能不全的准确界值。
  • 萎缩程度≥10%与肝衰竭死亡增加相关(0% vs 15%)。

核心结论

  • 广泛术前化疗诱导总肝体积显著萎缩性改变。
  • 萎缩程度≥10%是结直肠癌肝转移患者接受术前化疗和切除后术后肝功能不全和死亡的独立预测因素。

研究设计与样本

  • 回顾性分析2008—2015年接受术前化疗并根治性切除的结直肠癌肝转移患者的临床病理特征。
  • 研究队列共459例患者,其中154例(34%)接受广泛术前化疗(≥7周期)。
  • 萎缩程度定义为总肝体积(手工体积法估算)与标准化肝体积比值的百分比差值:([化疗前总肝体积]-[化疗后总肝体积])×100÷标准化肝体积(%)。
  • 采用受试者工作特征(ROC)分析确定预测术后肝功能不全的准确界值,采用Cox比例风险模型识别严重萎缩程度和术后肝功能不全的预测因素。

主要发现

  • ROC分析确定萎缩程度≥10%为预测术后肝功能不全的准确界值,该界值与≥7周期术前化疗显著相关。
  • 独立预测术后肝功能不全的四个因素:标准化未来肝残余≤30%(OR 4.03,p=0.019)、高天冬氨酸氨基转移酶与血小板比值指数(OR 5.27,p=0.028)、萎缩程度≥10%(OR 43.5,p<0.001)、大范围肝切除(OR 5.78,p=0.005)。
  • 萎缩程度≥10%与肝衰竭死亡增加相关(0%[0/374] vs 15%[13/85],p<0.001)。

关键数值与推荐

  • 萎缩程度≥10%为预测术后肝功能不全的准确界值。
  • 标准化未来肝残余≤30%预测术后肝功能不全的OR为4.03(p=0.019)。
  • 高天冬氨酸氨基转移酶与血小板比值指数预测术后肝功能不全的OR为5.27(p=0.028)。
  • 萎缩程度≥10%预测术后肝功能不全的OR为43.5(p<0.001)。
  • 大范围肝切除预测术后肝功能不全的OR为5.78(p=0.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: For patients with colorectal liver metastases (CLM) undergoing major hepatectomy, extensive preoperative chemotherapy has been associated with increased morbidity and mortality. The impact of extensive chemotherapy on total liver volume (TLV) change is unclear. The aims of the current study were twofold: (1) to determine the change of TLV following preoperative chemotherapy in patients undergoing resection for CLM and (2) to investigate the correlations among TLV change, postoperative hepatic insufficiency (PHI), and death from liver failure. METHODS: Clinicopathological features of patients with CLM who underwent preoperative chemotherapy and curative resection were reviewed (2008-2015). TLV change (degree of atrophy) was defined as the percentage difference of TLV (estimated by manual volumetry)/standardized liver volume (SLV) ratio: ([Pre-chemotherapy TLV]-[Post-chemotherapy TLV])×100÷SLV (%). Receiver operating characteristic (ROC) analysis was performed to decide the accurate cut-off value of degree of atrophy to predict PHI. The Cox proportional hazard model was performed to identify the predictors of severe degree of atrophy and PHI. RESULTS: The study cohort consisted of 459 patients, of which 154 patients (34%) underwent extensive preoperative chemotherapy (≥7 cycles). ROC analysis identified the degree of atrophy ≥10% as an accurate cut-off to predict PHI, which was significantly correlated with ≥7 cycles of preoperative chemotherapy. Four factors independently predicted PHI: standardized future liver remnant ≤30% (odds ratio [OR] 4.03, p=0.019), high aspartate aminotransferase-to-platelet ratio index (OR 5.27, p=0.028), degree of atrophy ≥10% (OR 43.5, p<0.001), and major hepatic resection (OR 5.78, p=0.005). Degree of atrophy ≥10% was associated with increased mortality from liver failure (0% [0/374] vs. 15% [13/85], p<0.001). CONCLUSION: Extensive preoperative chemotherapy induced significant atrophic change of TLV. Degree of atrophy ≥10% is an independent predictor of PHI and death in patients with CLM undergoing preoperative chemotherapy and resection. LAY SUMMARY: Extensive preoperative chemotherapy for patients with colorectal liver metastases (CLM) could induce hepatic atrophy. A higher degree of atrophy is an independent predictor of postoperative hepatic insufficiency and death in patients with CLM undergoing preoperative chemotherapy and resection.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yamashita S, Shindoh J, Mizuno T, et al. Hepatic atrophy following preoperative chemotherapy predicts hepatic insufficiency after resection of colorectal liver metastases. J Hepatol. 2017. PMID: 28192187. doi:10.1016/j.jhep.2017.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。